文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

现代放疗时代辅助放疗对最佳减瘤III期子宫内膜癌生存的影响

Impact of adjuvant radiotherapy on the survival of women with optimally resected stage III endometrial cancer in the era of modern radiotherapy: a retrospective study.
PubMed 文献 · Radiat Oncol · 2020-04-06

辅助治疗较单纯手术改善无复发生存(p=0.014)和总生存(p=0.044)。现代放疗技术辅助放疗急性≥2级胃肠道毒性25%、慢性7%。多因素分析显示非子宫内膜样组织学与复发风险增加相关(HR 2.95,p=0.009),辅助放疗单用或联合化疗与复发风险降低相关(HR 0.62,p=0.042)。

要点

  • 最佳减瘤III期子宫内膜癌辅助治疗可改善RFS和OS。
  • 现代放疗技术辅助放疗胃肠道毒性较低。
  • 非子宫内膜样组织学与复发风险增加独立相关。

核心结论

  • 现代辅助放疗(调强或容积旋转调强放疗)单用或联合化疗应考虑用于最佳减瘤的III期子宫内膜癌女性。

研究设计与样本

  • 辅助治疗包括现代放疗技术放疗、化疗或两者联合。
  • 采用Kaplan-Meier法计算无复发生存和总生存,并通过多因素Cox比例风险模型分析。

主要发现

  • 辅助治疗较单纯手术改善无复发生存(p=0.014)和总生存(p=0.044)。
  • 现代放疗技术辅助放疗急性≥2级胃肠道毒性发生率为25%,慢性≥2级为7%。
  • 单因素分析中,非子宫内膜样组织学和3级状态与肿瘤复发和死亡风险增高相关,辅助放疗单用或联合化疗降低这些风险。
  • 多因素分析中,非子宫内膜样组织学与复发风险增加相关(HR 2.95;p=0.009),辅助放疗单用或联合化疗与复发风险降低相关(HR 0.62;p=0.042)。
  • 年龄>60岁(p=0.038)、子宫内膜样组织学(p=0.045)、淋巴血管间隙浸润(p=0.031)和≥2枚阳性淋巴结(p=0.044)的患者从辅助放疗获益最大。

临床怎么用

  • 对最佳减瘤的III期子宫内膜癌女性,可考虑现代辅助放疗单用或联合化疗。
  • 非子宫内膜样组织学患者复发风险较高,应重视辅助放疗决策。
  • 年龄>60岁、子宫内膜样组织学、LVSI或≥2枚阳性淋巴结者可能从辅助放疗中更多获益。

局限性

  • 回顾性研究设计可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal adjuvant treatment for stage III endometrial cancer in the era of modern radiotherapy remains undefined. We investigated the benefit of adjuvant radiotherapy for women who underwent optimal resection for stage III endometrial cancer in the era of modern radiotherapy. METHODS: We retrospectively reviewed patients with endometrial cancer who were treated between 2010 and 2018. Adjuvant treatment included radiotherapy by modern radiotherapy techniques (intensity-modulated or volumetric modulated arc radiotherapy), chemotherapy, or both. Recurrence-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier method and analyzed via multivariate Cox proportional hazards models. RESULTS: One hundred sixty-one patients were initially included (52, 9, and 100 with stages IIIA, IIIB, and IIIC cancer, respectively); 154 patients (96%) received adjuvant therapy. Such adjuvant treatment was associated with improved RFS (p = 0.014) and OS (p = 0.044) over surgery alone. Adjuvant radiotherapy by modern radiotherapy techniques led to low incidence of acute (25%) and chronic (7%) grade ≥ 2 gastrointestinal toxicity. On univariate analysis, non-endometrioid histology and grade 3 status were associated with higher risks of tumor recurrence and death, whereas adjuvant radiotherapy alone or in combination chemotherapy reduced their risks. On multivariate analysis, non-endometrioid histology was associated with increased recurrence (hazard ratio [HR], 2.95; p = 0.009), whereas adjuvant radiotherapy alone or with chemotherapy was associated with lower recurrence (HR, 0.62; p = 0.042). Patients > 60 years of age (p = 0.038) as well as those with endometrioid histology (p = 0.045), lymphovascular space invasion (p = 0.031), and ≥ 2 positive lymph nodes (p = 0.044) benefited most from adjuvant radiotherapy. CONCLUSIONS: Modern adjuvant radiotherapy (intensity-modulated or volumetric modulated arc radiotherapy) alone or with chemotherapy should be considered for women with optimally resected stage III endometrial cancer. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04251676. Registered 24 January 2020. Retrospectively registered.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen JL, Huang YS, Huang CY, et al. Impact of adjuvant radiotherapy on the survival of women with optimally resected stage III endometrial cancer in the era of modern radiotherapy: a retrospective study. Radiat Oncol. 2020. PMID: 32252781. doi:10.1186/s13014-020-01523-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。